Hepatocellular carcinoma treatment: hurdles, advances and prospects

References

• Kumari R, Sharma A, Ajay AK, Bhatt M. Mitomycin C induces bystander killing in homogeneous and heterogeneous hepatoma cellular models. Mol. Cancer 8, 87 (2009).
   PubMed Web of Science ®Google Scholar
• Davis GL, Dempster J, Meler JD et al. Hepatocellular carcinoma: management of an increasingly common problem. Proc. (Bayl. Univ. Med. Cent.) 21(3), 266–280 (2008).
   PubMedGoogle Scholar
• Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin. Mol. Hepatol. 22(1), 7–17 (2016).
   PubMed Web of Science ®Google Scholar
• Gomma AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J. Hepatol. 7(4), 673–687 (2015).
   PubMedGoogle Scholar
• Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 30(6), 1434–1440 (1999).
   PubMed Web of Science ®Google Scholar
• Xu H, Mao Y. A brief comment on liver resection for hepatocellular carcinoma. Gastroenterol. Rep. (Oxf.) 1(3), 184–185 (2013).
   PubMedGoogle Scholar
• Bismuth H, Chiche L, Castaing D. Surgical treatment of hepatocellular carcinomas in noncirrhotic liver: experience with 68 liver resections. World J. Surg. 19, 35–41 (1995).
   PubMed Web of Science ®Google Scholar
• Kawasaki S, Makuuchi M, Miyagawa S et al. Results of hepatic resection for hepatocellular carcinoma. World J. Surg. 19, 31–34 (1995).
   PubMed Web of Science ®Google Scholar
• Vauthey JN, Klimstra D, Franceschi D et al. Hepatic resection for hepatocellular carcinoma. Am. J. Surg. 169, 28–35 (1995).
   PubMed Web of Science ®Google Scholar
• Yang T, Lin C, Zhai J et al. Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging. J. Cancer Res. Clin. Oncol. 138(7), 1121–1129 (2012).
   PubMed Web of Science ®Google Scholar
• Belghiti J, Ogata S. Assessment of hepatic reserve for the indication of hepatic resection. J. Hepatobiliary Pancreat. Surg. 12, 1–3 (2005).
   PubMedGoogle Scholar
• European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908–943 (2012).
   PubMed Web of Science ®Google Scholar
• Cooper A, Aloia TA. Surgical resection for hepatocellular carcinoma. Transl. Cancer Res. 2(6), 450–459 (2013).
   Web of Science ®Google Scholar
• Kishi Y, Abdalla EK, Chun YS et al. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann. Surg. 250, 540–548 (2009).
   PubMed Web of Science ®Google Scholar
• Portolani N, Coniglio A, Ghidoni S et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann. Surg. 243, 229–235 (2006).
   PubMed Web of Science ®Google Scholar
• Matsuda M, Fujii H, Kono H et al. Surgical treatment of recurrent hepatocellular carcinoma based on the mode of recurrence: repeat hepatic resection or ablation are good choices for patients with recurrent multicentric cancer. J. Hepatobiliary Pancreat. Surg. 8, 353–359 (2001).
   PubMedGoogle Scholar
• Huang ZY, Liang BY, Xiong M et al. Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China. Ann. Surg. Oncol. 19, 2515–2525 (2012).
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Chun YS, Poon RT et al. Liver transplantation for hepatocellular carcinoma. Ann. Surg. Oncol. 15, 1001–1007 (2008).
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334, 693–699 (1996).
   PubMed Web of Science ®Google Scholar
• Onaca N, Davis GL, Jennings LW et al. Improved results of transplantation for hepatocellular carcinoma: a report from the international registry of hepatic tumors in liver transplantation. Liver Transpl. 15, 574–580 (2009).
   PubMedGoogle Scholar
• Mehta N, Yao FY. Moving past ‘one size (and number) fits all’ in the selection of candidates with hepatocellular carcinoma for liver transplant. Liver Transpl. 19, 1055–1058 (2013).
   PubMed Web of Science ®Google Scholar
• Yao FY, Fidelman N. Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: where do we stand with tumor down-staging? Hepatology 63(3), 1014–1025 (2016).
   PubMed Web of Science ®Google Scholar
• Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J. Hepatol. 55(5), 1137–1147 (2011).
   PubMed Web of Science ®Google Scholar
• Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33, 1394–1403 (2001).
   PubMed Web of Science ®Google Scholar
• Prasad KR, Young RS, Burra P et al. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl. 17(Suppl. 2), S81–S89 (2011).
   PubMedGoogle Scholar
• Kim Y, Stahl CC, Makramalla A et al. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria. Surgery 162(6), 1250–1258 (2017).
   PubMed Web of Science ®Google Scholar
• Mehta N, Guy J, Frenette CT et al. Excellent outcomes of liver transplantation following down staging of hepatocellular carcinoma to within milan criteria: a multicenter study. Clin. Gastroenterol. Hepatol. 16(6), 955–964 (2018).
   PubMed Web of Science ®Google Scholar
• Malinchoc M, Kamath PS, Gordon FD et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31, 864–871 (2000).
   PubMed Web of Science ®Google Scholar
• Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33, 464–470 (2001).
   PubMed Web of Science ®Google Scholar
• Massie AB, Caffo B, Gentry SE et al. MELD exceptions and rates of waiting list outcomes. Am. J. Transplant. 11, 2362–2371 (2011).
   PubMed Web of Science ®Google Scholar
• Thandassery RB, Goenka U, Goenka MK. Role of local ablative therapy for hepatocellular carcinoma. J. Clin. Exp. Hepatol. 4, S104–S111 (2014).
   PubMedGoogle Scholar
• Brunello F, Veltri A, Carucci P et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand. J. Gastroenterol. 43, 727–735 (2008).
   PubMed Web of Science ®Google Scholar
• Lin SM, Lin CJ, Lin CC et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma< or =4 cm. Gastroenterology 127, 1714–1723 (2004).
   PubMed Web of Science ®Google Scholar
• Lencioni R, Cioni D, Crocetti L et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 234(3), 961–967 (2005).
   PubMed Web of Science ®Google Scholar
• Yang B, Zan RY, Wang SY et al. Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. World J. Surg. Oncol. 13, 96 (2015).
   PubMed Web of Science ®Google Scholar
• Chen MS, Li JQ, Zheng Y et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann. Surg. 243, 321–328 (2006).
   PubMed Web of Science ®Google Scholar
• Guglielmi A, Ruzzenente A, Valdegamberi A et al. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J. Gastrointest. Surg. 12, 192–198 (2008).
   PubMed Web of Science ®Google Scholar
• Feng Q, Chi Y, Liu Y, Zhang L, Liu Q. Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies. J. Cancer Res. Clin. Oncol. 141(1), 1–9 (2015).
   PubMed Web of Science ®Google Scholar
• Otto G, Schuchmann M, Hoppe-Lotichius M et al. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? J. Hepatol. 59(2), 279–284 (2013).
   PubMed Web of Science ®Google Scholar
• Wáng YXJ, De Baere T, Idée JE, Ballet S. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin. J. Cancer Res. 27(2), 96121 (2015).
   Web of Science ®Google Scholar
• Luz JH, Luz PM, Martin HS et al. DEB TACE for intermediate and advanced HCC: initial experience in a Brazilian Cancer Center. Cancer Imaging 17(1), 5 (2017).
   PubMedGoogle Scholar
• Clark TW. Complications of hepatic chemoembolization. Semin. Intervent. Radiol. 23, 119–125 (2006).
   PubMedGoogle Scholar
• Leung DA, Goin JE, Sickles C et al. Determinants of postembolization syndrome after hepatic chemoembolization. J. Vasc. Interv. Radiol. 12, 321–326 (2001).
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 53, 1020–1022 (2011).
   PubMed Web of Science ®Google Scholar
• Marelli L, Stigliano R, Triantos C et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc. Intervent. Radiol. 30, 6–25 (2007).
   PubMed Web of Science ®Google Scholar
• Sacco R, Conte C, Tumino E et al. Transarterial radioembolization for hepatocellular carcinoma: a review. J. Hepatocell. Carcinoma 3, 25–29 (2016).
   PubMedGoogle Scholar
• Cho YY, Lee M, Kim HC et al. Radioembolization is a safe and effective treatment for hepatocellular carcinoma with portal vein thrombosis: a propensity score analysis. PLoS ONE 11(5), e0154986 (2016).
   PubMed Web of Science ®Google Scholar
• Kim HC. Radioembolization for the treatment of hepatocellular carcinoma. Clin. Mol. Hepatol. 23(2), 109–114 (2017).
   PubMed Web of Science ®Google Scholar
• Ricke J, Bulla K, Kolligs F et al. Safety and toxicity of radioembolization plus sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. Liver Int. 35(2), 620–626 (2015).
   PubMed Web of Science ®Google Scholar
• Vilgrain V, Abdel-Rehim M, Sibert A et al. Radioembolisation with yttrium90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials 15, 474 (2014).
   PubMed Web of Science ®Google Scholar
• Clinical Trials With TheraSphere® YTTRIUM-90 GLASS MICROSPHERES. 2016. www.therasphere.com/clinicaltrials_us/index.asp.
   Google Scholar
• Clinicaltrials.gov. Study to compare selective internal radiation therapy (SIRT) versus sorafenib in locally advanced hepatocellular carcinoma (HCC) (SIRveNIB) (2014). https://clinicaltrials.gov/ct2/show/study/NCT01135056?term=01135056&rank=1.
   Google Scholar
• Lai CL, Wu PC, Chan GC et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62, 47983 (1988).
   Web of Science ®Google Scholar
• Leung TW, Patt YZ, Lau WY et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin. Cancer Res. 5, 1676–1681 (1999).
   PubMed Web of Science ®Google Scholar
• Yeo W, Mok TS, Zee B et al. A randomized Phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl Cancer Inst. 97, 1532–1538 (2005).
   PubMed Web of Science ®Google Scholar
• Moeini A, Cornellà H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer 1(2), 83–93 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang ZL, Liu ZS, Sun Q. Expression of angiopoitins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J. Gastroenterol. 12, 4241–4245 (2006).
   PubMed Web of Science ®Google Scholar
• Faivre S, Raymond E, Boucher E et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, Phase II study. Lancet Oncol. 10, 794–800 (2009).
   PubMed Web of Science ®Google Scholar
• Albert DH, Tapang P, Magoc TJ et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 5(4), 995–1006 (2006).
   PubMed Web of Science ®Google Scholar
• Toh HC, Chen PJ, Carr BI et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 119(2), 380–387 (2013).
   PubMed Web of Science ®Google Scholar
• Bhide RS, Lombardo LJ, Hunt JT et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol. Cancer Ther. 9, 369–378 (2010).
   PubMed Web of Science ®Google Scholar
• Jhonson PJ, Qin S, Park JW et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized Phase III Brisk-FL study. J. Clin. Oncol. 31(28), 3509–3516 (2013).
   PubMed Web of Science ®Google Scholar
• Keating GM, Santoro A. Sorafenib a review of its use in advanced hepatocellular carcinoma. Drugs 69(2), 223–240 (2009).
   PubMed Web of Science ®Google Scholar
• Sorafenib, package insert. Bayer Healthcare Pharmaceuticals, Inc. CA, USA. http://berlex.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf.
   Google Scholar
• Pawlik TM, Reyes TK, Cosgrove D et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J. Clin. Oncol. 29(30), 3960–3967 (2011).
   PubMed Web of Science ®Google Scholar
• Salman A, Simoneau E, Hassanain M et al. Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma. Curr. Oncol. 23(5), e472–e480 (2016).
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Johnson P, Knox JJ et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304(19), 2154–2160 (2010).
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Lin DY et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized Phase III trial. J. Clin. Oncol. 31, 4067–4075 (2013).
   PubMed Web of Science ®Google Scholar
• Cainap C, Qin S, Huang WT et al. Linifanib verses sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 33, 172–179 (2014).
   PubMed Web of Science ®Google Scholar
• Zhu AX, Rosmorduc O, Evans TRJ et al. SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 33, 559–566 (2014).
   PubMed Web of Science ®Google Scholar
• Jeay S, Munshi N, Hill J et al. ARQ 197, a highly selective small molecule inhibitor of c-MET, with selective anti-tumor properties in a broad spectrum of human cancer cells. Presented at: AACR Annual Meeting. CA, USA, 14–18 April 2007 ( Abstract 2369).
   Google Scholar
• Santoro A, Rimassa L, Borbath I et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled Phase ii study. Lancet Oncol. 14(1), 55–63 (2013).
   PubMed Web of Science ®Google Scholar
• Martell RE, Puzanov I, Ma WW et al. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a hepatocellular carcinoma (HCC) from a Phase I study. J. Clin. Oncol. 30(Suppl.), Abstract 4117 (2012).
   PubMedGoogle Scholar
• Study of tivantinib in subjects with inoperable hepatocellular carcinoma who have been treated with one prior therapy (METIV HCC). www.clinicaltrials.gov/ct2/show/NCT017557.
   Google Scholar
• Martin V, Liu D, Fueyo J, Gomez-Manzano C. Tie2: a journey from normal angiogenesis to cancer and beyond. Histol. Histopathol. 23(6), 773–780 (2008).
   PubMed Web of Science ®Google Scholar
• Frennette CT. The role of regorafenib in hepatocellular carcinoma. Gastroenterol. Hepatol. (N Y). 13(2), 122–124 (2017).
   PubMedGoogle Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).
   PubMed Web of Science ®Google Scholar
• Turkbey B, Kobayashi H, Ogawa M, Bernardo M, Choyke PL. Imaging of tumor angiogenesis: functional or targeted? AJR Am. J. Roentgenol. 193(2), 304–313 (2009).
   PubMed Web of Science ®Google Scholar
• Kaji K, Yoshiji H, Ikenaka Y et al. Possible involvement of angiogenesis in chronic liver diseases: interaction among renin–angiotensin–aldosterone system, insulin resistance and oxidative stress. Curr. Med. Chem. 19(12), 1889–1898 (2012).
   PubMed Web of Science ®Google Scholar
• Huang W, Wu YL, Zhong J et al. Angiotensin II type 1 receptor antagonist suppress angiogenesis and growth of gastric cancer xenografts. Dig. Dis. Sci. 53(5), 1206–1210 (2008).
   PubMed Web of Science ®Google Scholar
• Kaji K, Yoshiji H, Kitade M et al. Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice. Hepatol. Res. 40(5), 540–549 (2010).
   PubMed Web of Science ®Google Scholar
• Bae SY, Kim HJ, Oh HH et al. Multiple bone metastases as the first manifestation of hepatocellular carcinoma in patient with noncirrhotic liver. Case Rep. Oncol. Med. 2015, 512849 (2015).
   PubMedGoogle Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 42, 1208–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Li S, Li Q. Cancer stem cells and tumor metastasis (Review). Int. J. Oncol. 4, 1806–1812 (2014).
   Google Scholar
• Sie M, den Dunnen WF, Hoving EW et al. Antiangiogenic therapy in pediatric brain tumors: an effective strategy? Crit. Rev. Oncol. Hematol. 89(3), 418–432 (2014).
   PubMed Web of Science ®Google Scholar
• Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 57, 399–408 (2013).
   PubMed Web of Science ®Google Scholar
• Baumert TF, Jühling F, Ono A, Hoshida Y. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med. 15(1), 52 (2017).
   PubMedGoogle Scholar
• Cooper DKC, Dou KF, Tao KS et al. Pig liver xenotransplantation: a review of progress toward the clinic. Transplantation 100, 2039–2047 (2016).
   PubMed Web of Science ®Google Scholar
• Dhawan A, Puppi J, Hughes RD, Mitry RR. Human hepatocyte transplantation: current experience and future challenges. Nature Rev. Gastroenterol. Hepatol. 7, 288–298 (2010).
   PubMed Web of Science ®Google Scholar
• Dhawan A. Clinical human hepatocyte transplantation: current status and challenges. Liver Transpl. 21, S39–S44 (2015).
   PubMed Web of Science ®Google Scholar
• Eiseman B, Liem DS, Raffucci F. Heterologous liver perfusion in treatment of hepatic failure. Ann. Surg. 162, 329–345 (1965).
   PubMed Web of Science ®Google Scholar
• Matsumura K, Guevara G, Huston H et al. Hybrid bioartificial liver in hepatic failure: preliminary clinical report. Surgery 101, 99–103 (1987).
   PubMed Web of Science ®Google Scholar
• Sakai Y, Naruse K, Nagashima I et al. Large-scale preparation and function of porcine hepatocyte spheroids. Int. J. Artif. Organs 19(5), 294–301 (1996).
   PubMed Web of Science ®Google Scholar
• Xiang ZL, Zeng ZC, Fan J et al. The expression of HIF-1α in primary hepatocellular carcinoma and its correlation with radiotherapy response and clinical outcome. Mol. Biol. Rep. 39, 2021–2029 (2012).
   PubMed Web of Science ®Google Scholar